GRACE :: Lung Cancer


Denise Brock

2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know – Faculty










Dr. Stephen Liu

Dr. Stephen V. Liu is an Assistant Professor of Medicine and a practicing thoracic medical oncologist at the Lombardi Comprehensive Cancer Center at Georgetown University. He received his undergraduate degree at Johns Hopkins University and his medical degree at the University of Maryland. He then completed his internship and residency in Internal Medicine at the University of Pennsylvania and his fellowship training in Hematology and Oncology at the University of Southern California before joining the faculty of Georgetown University. Dr. Liu specializes in the treatment of lung cancer and leads an active research program at Georgetown University focused on rational drug development and the study of novel small molecule and immunotherapy treatment strategies. In addition to leading national and global clinical trials for the treatment of lung cancer, Dr. Liu also serves as chief editor for the medical journal Frontiers in Thoracic Oncology


Dr. Benjamin Levy

Dr. Benjamin Levy is a thoracic medical oncologist and the clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital, as well as an assistant professor of oncology for Johns Hopkins University School of Medicine. Dr. Levy is board certified in medical oncology and hematology by the American Board of Internal Medicine. He practices out of the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital. 

Dr. Levy is a physician-scientist who is interested in innovative immunotherapeutic approaches for advanced stage lung cancer patients and biomarkers that help define those patients more likely to respond to such agents. He has an expertise in thoracic malignancies, including non-small cell lung cancer, small cell lung cancer, and thymic malignancies, as well as head and neck cancer. 

Dr. Levy earned his medical degree from Medical College of Georgia. He completed an internal medicine residency at Georgetown University Hospital, followed by a hematology/oncology fellowship at New York Presbyterian/Weill Cornell Medical Center, where he received the Department of Medicine Research Fellow of the Year Award and the 2009 American Society of Clinical Oncology Young Investigator Award for his clinical research in prostate cancer. Dr. Levy previously worked as an assistant professor at the Icahn School of Medicine, medical director of thoracic oncology for Mount Sinai Health Systems and associate director of the Cancer Clinical Trials Office for Mount Sinai Hospital in New York City. 

Dr. Levy played an integral role in several American Society of Clinical Oncology (ASCO) committees and currently serves as associate editor for the ASCO University Committee. He completed a two-year term on the editorial board for the Journal of Clinical Oncology and currently serves as an ad hoc reviewer for other journals, including Clinical Lung CancerThe Oncologist, and Oncotarget. Dr. Levy was recently selected as one of only 15 oncologists in the country to the prestigious ASCO Leadership Development program, whose mission is to identify and develop future leaders of ASCO. In addition to his ASCO commitments, Dr. Levy serves on the ALLIANCE Respiratory Committee, the IASLC Staging Committee, and the IASLC Career Development & Fellowship Committee.


Dr. Alex Spira

A graduate of Harvard University, Dr. Alex Spira earned his medical degree from the New York University School of Medicine. He then went on to complete his internship and residency at the Hospital of the University of Pennsylvania, and he completed his medical oncology fellowship at Johns Hopkins Hospital. During his training, Dr. Spira was granted many awards and honors, and he completed several specialized fellowship programs. Among these honors were the National Institutes of Health Medical Scientist Training Program Fellowship (1990-1997), Merck Corporation Scholarship (1995-1995), Pediatric AIDS Foundation Fellowship (1993-1995) and Harvard University Scholarship (1987-1990). Dr. Spira has also received his PhD from the New York University School of Arts and Sciences.

As Director of the VCS Research Institute and the Phase I Trial Program, Dr. Spira is actively involved in advancing medicine and targeted treatment options for patients. Although his research interests are numerous, Dr. Spira particularly enjoys studying immunotherapy, personalized medicine, GI and thoracic cancers, and lung cancers. Dr. Spira also serves as the Medical Director for the Inova Thoracic Oncology Program and as Chair of the US Oncology Pathways Taskforce Committee for Lung Cancer. Dr. Spira is a member of the American Society of Clinical Oncology, the American Society of Hematology, the American Association of Cancer Research, the US Oncology Translational Oncology Program, the US Oncology Lung Cancer Program, and the International Society for the Advancement of Lung Cancer. Additionally, Dr. Spira is a Fellow of the American College of Physicians and author of various publications.

Throughout his career, Dr. Spira has received multiple honors, including Top Doctor in Northern Virginia Magazine and Washingtonian magazine for multiple years. In 2014, he received the prestigious Castle Connolly America’s Top Doctor award. In his spare time, Dr. Spira enjoys spending time with his family, coaching children’s sports, cycling, and cheering on his favorite New York sports teams.